Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment

Journal of Hepatology
January 1, 2017
Cited by 12

Abstract


Related Papers

No related papers found

Powered by citation graph analysis